Virus News and Research

Latest Virus News and Research

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

News outlets examine use of ART, microbicide development presented at conference

News outlets continue to report on the science discussed at the Conference on Retroviruses and Opportunistic Infections (CROI), which ended Friday in San Francisco.

23 Feb 2010

PositiveID, RECEPTORS announce successful completion of rapid virus detection system Phase I development

PositiveID Corporation, in conjunction with its development partner RECEPTORS LLC, announced today that it has successfully completed Phase I development of its rapid virus detection system, a non-invasive, point-of-care test to test patient samples and identify various forms of influenza within minutes. Phase II of the development, which the Company expects to complete by the end of 2010, is planned to launch in February 2010.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

UCI researchers create new breed of flightless mosquitoes for dengue control

UCI researchers and colleagues from Oxitec Ltd. and the University of Oxford created the new breed. Flightless females are expected to die quickly in the wild, curtailing the number of mosquitoes and reducing - or even eliminating - dengue transmission. Males of the strain can fly but do not bite or convey disease.

23 Feb 2010

AAAS meeting examines test-and-treat model's potential for fighting HIV spread, TB co-infection

Researchers speaking at the American Association for the Advancement of Science (AAAS) meeting on Saturday, discussed how a strategy to promote universal voluntary HIV tests and early antiretroviral treatment for patients living in high-risk areas might "derail the spread of [HIV/]AIDS, a battle where a successful vaccine remains elusive," the Associated Press/Washington Post reports

23 Feb 2010

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

A new guideline from the American Academy of Neurology recommends that the drug quinine, although effective, should be avoided for treatment of routine muscle cramps due to uncommon but serious side effects.

23 Feb 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

HHS Secretary reviews H1N1 response at NACCHO conference

Thank you, Tom. I also want to thank NACCHO for hosting this important conference and for inviting me to speak here today. Public health is a top priority for this administration. So is strengthening our partnerships across government. So I’m glad I could come talk with you about how we can work together to keep Americans healthy and safe.

22 Feb 2010

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

Many people who undergo treatment for hepatitis C develop hemolytic anemia, a disorder that destroys red blood cells. In some cases, it is so severe they have to reduce their medication or stop therapy altogether. But now, scientists in Duke University's Institute for Genome Sciences & Policy have discovered two genetic alterations linked to a benign enzyme condition that keep some patients anemia-free.

21 Feb 2010

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

Influenza surveillance mechanisms in Mexico were adequate during the fast-spreading H1N1 outbreak in 2009, yet Mexico did not have the infrastructure to quickly identify the emergence of this novel strain, according to an Arizona State University (ASU) epidemiologist.

21 Feb 2010

News outlets examine HIV vaccine research, cervical cancer screening data presented at conference

Several news outlets examine the latest reports out of this week's Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

20 Feb 2010

Quidel acquires Diagnostic Hybrids for $130 million

Quidel Corporation, a leading provider of rapid diagnostic tests, has completed its previously announced acquisition of Diagnostic Hybrids, Inc. for approximately $130 million in cash.

20 Feb 2010

GenVec announces new contract with DHS to develop adenovector-based vaccines against FMD

Today GenVec, Inc. announced a new contract with the Department of Homeland Security to continue the development of adenovector-based vaccines against foot-and-mouth disease (FMD) based on research and development done in collaboration with USDA-ARS and DHS S&T scientists at the Plum Island Animal Disease Center.

19 Feb 2010

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Novavax, Inc. today presented to the world's leading pandemic influenza vaccine experts a summary of the recent preliminary safety and immunogenicity data from its Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study in Mexico.

19 Feb 2010

Amerigroup's fourth-quarter revenues rise 18.5%

Amerigroup Corporation today announced that net income for the fourth quarter of 2009 was $40.2 million, or $0.79 per diluted share, versus $35.9 million, or $0.67 per diluted share, for the fourth quarter of 2008. For the year ended December 31, 2009, the Company's net income was $149.3 million, or $2.85 per diluted share.

19 Feb 2010

State policy developments: Wisconsin's new 'public option,' Iowa's medical marijuana vote, and more

New Hampshire Public Radio: A bill in the state legislature would create an annual public report that details the causes of rising health spending by analyzing now-private information that doctors, hospitals and other health organizations would have to provide to the state's Department of Insurance. The move is partly in response to conflicting narratives: The state's health spending continues to rise, yet hospitals and doctors say they are struggling (Grant, 2/17).

19 Feb 2010

Simple molecular kit to reprogram any cell of the body into another

In an effort to sidestep the ethical dilemma involved in using human embryonic stem cells to treat diseases, scientists are developing non-controversial alternatives: In particular, they are looking for drug-like chemical compounds that can transform adult skin cells into the stem cells now obtained from human embryos. That's the topic of a fascinating article in Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

19 Feb 2010

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases such as HIV and cardiovascular diseases, announced results from its prophylactic HIV vaccine (VRX1023) study in Rhesus Macaque monkeys during a presentation today at the 2010 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA.

19 Feb 2010

Researchers develop technology to preserve vaccines in tropical temperatures

A team of British researchers have developed a simple, low-cost method to preserve vaccines in tropical climates, which they say could help to revolutionalize vaccination campaigns in developing countries, Reuters reports.

19 Feb 2010

Virus News and Research

Latest Virus News and Research

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

News outlets examine use of ART, microbicide development presented at conference

PositiveID, RECEPTORS announce successful completion of rapid virus detection system Phase I development

Study shows CEL-2000 vaccine blocks RA progression in mice

UCI researchers create new breed of flightless mosquitoes for dengue control

AAAS meeting examines test-and-treat model's potential for fighting HIV spread, TB co-infection

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

HHS Secretary reviews H1N1 response at NACCHO conference

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

News outlets examine HIV vaccine research, cervical cancer screening data presented at conference

Quidel acquires Diagnostic Hybrids for $130 million

GenVec announces new contract with DHS to develop adenovector-based vaccines against FMD

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Amerigroup's fourth-quarter revenues rise 18.5%

State policy developments: Wisconsin's new 'public option,' Iowa's medical marijuana vote, and more

Simple molecular kit to reprogram any cell of the body into another

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

Researchers develop technology to preserve vaccines in tropical temperatures

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Virus News and Research

Latest Virus News and Research

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Newsletters you may be interested in